Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 13,827 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00.

Health Catalyst Price Performance

Shares of HCAT opened at $4.17 on Wednesday. The company has a 50 day moving average of $5.62 and a two-hundred day moving average of $7.11. The company has a market cap of $292.78 million, a price-to-earnings ratio of -3.09 and a beta of 1.41. Health Catalyst, Inc. has a twelve month low of $3.76 and a twelve month high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HCAT. Wells Fargo & Company dropped their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Stifel Nicolaus dropped their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Piper Sandler dropped their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Canaccord Genuity Group dropped their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Finally, Stephens dropped their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HCAT. First Light Asset Management LLC raised its holdings in shares of Health Catalyst by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock worth $37,055,000 after buying an additional 944,631 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after buying an additional 861,150 shares during the last quarter. Fred Alger Management LLC purchased a new position in shares of Health Catalyst in the third quarter worth $6,858,000. Portolan Capital Management LLC purchased a new position in shares of Health Catalyst in the third quarter worth $5,402,000. Finally, Kennedy Capital Management LLC raised its holdings in shares of Health Catalyst by 42.7% in the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock worth $13,369,000 after buying an additional 565,445 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.